| Drug
Class |
Agents
and Daily Doses |
Lipid/Lipoprotein
Effects |
Side
Effects |
Contraindications |
HMG CoA
reductase
inhibitors (statins) |
Lovastatin
(20-80 mg),
Pravastatin (20-40 mg),
Simvastatin (20-80 mg),
Fluvastatin (20-80 mg),
Atorvastatin (10-80 mg),
Cerivastatin (0.4-0.8 mg) |
LDL-C
18-55%
HDL-C 5-15%
TG 7-30% |
Myopathy
Increased liver
enzymes |
Absolute:
Active or chronic liver
disease
Relative:
Concomitant use of certain
drugs* |
Bile
acid
Sequestrants |
Cholestyramine
(4-16 g)
Colestipol (5-20 g)
Colesevelam (2.6-3.8 g) |
LDL-C
15-30%
HDL-C 3-5%
TG No change or
increase |
Gastrointestinal
distress
Constipation
Decreased
absorption of other
drugs |
Absolute:
dysbeta-lipoproteinemia
TG >400 mg/dL
Relative:
TG >200 mg/dL |
| Nicotinic
acid |
Immediate
release (crystalline)
nicotinic acid (1.5-3 gm),
extended release nicotinic acid
(Niaspan ®) (1-2 g), sustained
release nicotinic acid (1-2 g) |
LDL-C
5-25%
HDL-C 15-35%
TG 20-50% |
Flushing
Hyperglycemia
Hyperuricemia (or
gout)
Upper GI distress
Hepatotoxicity |
Absolute:
Chronic liver disease
Severe gout
Relative:
Diabetes
Hyperuricemia
Peptic ulcer disease |
| Fibric
acids |
Gemfibrozil
(600 mg BID)
Fenofibrate (200 mg)
Clofibrate (1000 mg BID) |
LDL-C
5-20%
(may
be increased in patients
with high TG)
HDL-C 10-20%
TG 20-50% |
Dyspepsia
Gallstones
Myopathy |
Absolute:
Severe renal disease
Severe hepatic disease |